2 december 2017: klik op de titels

Conclusions and Relevance  Minimal residual disease-negative status after treatment for newly diagnosed MM is associated with long-term survival. These findings provide quantitative evidence to support the integration of MRD assessment as an end point in clinical trials of MM.

Traditionally considered a death sentence, multiple myeloma is now being described as a potentially curable disease. The improving survival rate is largely attributed to a profusion of new treatment options and the growing ability to individualize therapy for patients at each stage of their disease. But given the number of treatment options available, many physicians are uncertain about which therapies to use and when to use them. The oncology team from the Mayo Clinic in Scottsdale, Arizona, provides guidance on how to navigate the new therapeutic terrain of multiple myeloma.


Plaats een reactie ...

Reageer op "Meta-analysis Shows Association of Minimal Residual Disease–Negative Status With Improved Survival in Multiple Myeloma"


Gerelateerde artikelen
 

Gerelateerde artikelen

Nederlandse studie geeft overzicht >> Belangrijke abstracten van >> CAR T-celtherapie met het >> Meta-analysis Shows Association >> Hoewel overall overleving >> Cryotherapie tijdens toediening >> Daratumumab (Darzalex) in >> Elotuzumab - een immuuntherapeutisch >> Genentest blijkt voorspellende >> lenalidomide na autologe stamceltransplantatie >>